Mitochondrial medicine has transitioned from the realm of cellular organelle genetics into active clinical peptide therapeutics. New investigations emerging from cellular biology centers highlight the role of mitochondrial-derived peptides (MDPs), specifically MOTS-c and Humanin, in coordinating muscle bioenergetics under pathological metabolic stress.
MOTS-c acts as an autonomous systemic messenger that translocates from mitochondria to the cell nucleus during cellular energy deprivation. By phosphorylating AMP-activated protein kinase (AMPK) and regulating the folate cycle, MOTS-c promotes metabolic flexibility and preserves mitochondrial cristae integrity.
Ongoing clinical investigations are exploring whether synthetic MOTS-c can prevent cancer cachexia, muscle wasting, and mitochondrial fatigue in patients undergoing intensive chemotherapy regimens.